Serum YKL-40, but Not Relaxin-2, Shows Diagnostic Utility as an Adjunct Biomarker in Colorectal Cancer.

Kamil Safiejko, Marcin Juchimiuk, Julia Doroszkiewicz, Barbara Mroczko, Monika Zajkowska

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Chitinase-like Proteins YKL-40 and YKL-39 in Colorectal Cancer.Cells · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Kamil SafiejkoDepartment of Oncological Surgery with Specialized Cancer Treatment Units, Maria Sklodowska-Curie Oncology Center, 15-027 Bialystok, Poland.ORCID 0000-0003-0373-9911

Marcin JuchimiukDepartment of Oncological Surgery with Specialized Cancer Treatment Units, Maria Sklodowska-Curie Oncology Center, 15-027 Bialystok, Poland.

Julia DoroszkiewiczDepartment of Biochemical Diagnostics, Medical University of Bialystok Clinical Hospital, 15-269 Bialystok, Poland.ORCID 0000-0001-9937-4974

Barbara MroczkoDepartment of Biochemical Diagnostics, Medical University of Bialystok Clinical Hospital, 15-269 Bialystok, Poland.ORCID 0000-0002-4075-8479

Monika ZajkowskaDepartment of Biochemical Diagnostics, Medical University of Bialystok Clinical Hospital, 15-269 Bialystok, Poland.ORCID 0000-0002-5179-0722

Funding

Medical University of Białystok B.SUB.25.517

6 · The paper itself

Abstract

Despite the availability of conventional serum markers for colorectal cancer (CEA, CA 19-9), there remains a need for more sensitive and specific biomarkers, particularly for early-stage detection. This study evaluated the diagnostic usefulness of serum Relaxin-2 (RLN2) and Chitinase-3-like protein 1 (YKL-40) as potential adjunct markers in patients with CRC. Serum concentrations of all the proteins were measured using a multiplexing assay and CMIA and were subsequently compared using non-parametric statistical tests. The concentrations of YKL-40, CEA, and CA 19-9 were elevated in CRC patients relative to controls (

Indexed as

Biomarkers, TumorChitinase-3-Like Protein 1Colorectal NeoplasmsRelaxinAdultAgedAged, 80 and overCA-19-9 AntigenCarcinoembryonic AntigenFemaleHumansMaleMiddle AgedBiomarkers, TumorCA-19-9 AntigenCarcinoembryonic AntigenCHI3L1 protein, humanChitinase-3-Like Protein 1RelaxinRLN2 protein, humanbiomarker discoveryCHI3L1diagnostic panelRLN2serum diagnostics

Identifiers

PMID41373753

DOI10.3390/ijms262311601

PMCPMC12691882

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.